Roche buys Mirus in $125M deal

Roche is continuing its buying spree with a deal to acquire Madison, WI-based Mirus Bio for $125 million. Mirus specializes in developing nucleic acid-based therapies, which includes RNAi technology for gene silencing.

"The technology brought by Mirus, together with additional technologies, will bring us closer to creating fully-enabled RNAi therapeutics," said Lee Babiss, global head of Roche pharma research.

- check out the release
- read the report from Hays Pharma

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.